<SEC-DOCUMENT>0000950170-25-094002.txt : 20250703
<SEC-HEADER>0000950170-25-094002.hdr.sgml : 20250703
<ACCEPTANCE-DATETIME>20250703173005
ACCESSION NUMBER:		0000950170-25-094002
CONFORMED SUBMISSION TYPE:	4
PUBLIC DOCUMENT COUNT:		1
CONFORMED PERIOD OF REPORT:	20250701
FILED AS OF DATE:		20250703
DATE AS OF CHANGE:		20250703

REPORTING-OWNER:	

	OWNER DATA:	
		COMPANY CONFORMED NAME:			Simon Amy
		CENTRAL INDEX KEY:			0001963879
		ORGANIZATION NAME:           	

	FILING VALUES:
		FORM TYPE:		4
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39208
		FILM NUMBER:		251106468

	MAIL ADDRESS:	
		STREET 1:		BEAM THERAPEUTICS, INC.
		STREET 2:		238 MAIN STREET, 9TH FL.
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02142

ISSUER:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Beam Therapeutics Inc.
		CENTRAL INDEX KEY:			0001745999
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	BUSINESS ADDRESS:	
		STREET 1:		26 LANDSDOWNE STREET
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02139
		BUSINESS PHONE:		857-327-8775

	MAIL ADDRESS:	
		STREET 1:		26 LANDSDOWNE STREET
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02139
</SEC-HEADER>
<DOCUMENT>
<TYPE>4
<SEQUENCE>1
<FILENAME>ownership.xml
<DESCRIPTION>4
<TEXT>
<XML>
<?xml version="1.0"?>
<ownershipDocument>

    <schemaVersion>X0508</schemaVersion>

    <documentType>4</documentType>

    <periodOfReport>2025-07-01</periodOfReport>

    <issuer>
        <issuerCik>0001745999</issuerCik>
        <issuerName>Beam Therapeutics Inc.</issuerName>
        <issuerTradingSymbol>BEAM</issuerTradingSymbol>
    </issuer>

    <reportingOwner>
        <reportingOwnerId>
            <rptOwnerCik>0001963879</rptOwnerCik>
            <rptOwnerName>Simon Amy</rptOwnerName>
        </reportingOwnerId>
        <reportingOwnerAddress>
            <rptOwnerStreet1>C/O BEAM THERAPEUTICS INC.,</rptOwnerStreet1>
            <rptOwnerStreet2>238 MAIN STREET</rptOwnerStreet2>
            <rptOwnerCity>CAMBRIDGE</rptOwnerCity>
            <rptOwnerState>MA</rptOwnerState>
            <rptOwnerZipCode>02142</rptOwnerZipCode>
            <rptOwnerStateDescription></rptOwnerStateDescription>
        </reportingOwnerAddress>
        <reportingOwnerRelationship>
            <isDirector>false</isDirector>
            <isOfficer>true</isOfficer>
            <isTenPercentOwner>false</isTenPercentOwner>
            <isOther>false</isOther>
            <officerTitle>Chief Medical Officer</officerTitle>
        </reportingOwnerRelationship>
    </reportingOwner>

    <aff10b5One>true</aff10b5One>

    <nonDerivativeTable>
        <nonDerivativeTransaction>
            <securityTitle>
                <value>Common Stock</value>
            </securityTitle>
            <transactionDate>
                <value>2025-07-01</value>
            </transactionDate>
            <transactionCoding>
                <transactionFormType>4</transactionFormType>
                <transactionCode>S</transactionCode>
                <equitySwapInvolved>false</equitySwapInvolved>
                <footnoteId id="F1"/>
            </transactionCoding>
            <transactionAmounts>
                <transactionShares>
                    <value>374</value>
                </transactionShares>
                <transactionPricePerShare>
                    <value>16.9423</value>
                </transactionPricePerShare>
                <transactionAcquiredDisposedCode>
                    <value>D</value>
                </transactionAcquiredDisposedCode>
            </transactionAmounts>
            <postTransactionAmounts>
                <sharesOwnedFollowingTransaction>
                    <value>65740</value>
                    <footnoteId id="F2"/>
                </sharesOwnedFollowingTransaction>
            </postTransactionAmounts>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>D</value>
                </directOrIndirectOwnership>
            </ownershipNature>
        </nonDerivativeTransaction>
        <nonDerivativeTransaction>
            <securityTitle>
                <value>Common Stock</value>
            </securityTitle>
            <transactionDate>
                <value>2025-07-03</value>
            </transactionDate>
            <transactionCoding>
                <transactionFormType>4</transactionFormType>
                <transactionCode>S</transactionCode>
                <equitySwapInvolved>false</equitySwapInvolved>
                <footnoteId id="F3"/>
            </transactionCoding>
            <transactionAmounts>
                <transactionShares>
                    <value>876</value>
                </transactionShares>
                <transactionPricePerShare>
                    <value>20.1200</value>
                </transactionPricePerShare>
                <transactionAcquiredDisposedCode>
                    <value>D</value>
                </transactionAcquiredDisposedCode>
            </transactionAmounts>
            <postTransactionAmounts>
                <sharesOwnedFollowingTransaction>
                    <value>64864</value>
                </sharesOwnedFollowingTransaction>
            </postTransactionAmounts>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>D</value>
                </directOrIndirectOwnership>
            </ownershipNature>
        </nonDerivativeTransaction>
    </nonDerivativeTable>

    <footnotes>
        <footnote id="F1">These shares of common stock were automatically sold in a non-discretionary transaction by the Reporting Person in order to cover tax withholding obligations upon the vesting of certain restricted stock units granted to the Reporting Person under the Beam Therapeutics Inc. (&quot;BEAM&quot;) 2019 Equity Incentive Plan on June 30, 2022. The sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 19, 2023.</footnote>
        <footnote id="F2">Includes 372 shares acquired by the Reporting Person under the BEAM Amended and Restated 2019 Employee Stock Purchase Plan on September 30, 2024.</footnote>
        <footnote id="F3">These shares of common stock were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 7, 2024.</footnote>
    </footnotes>

    <ownerSignature>
        <signatureName>By: /s/ Christine Bellon, Attorney-in-fact</signatureName>
        <signatureDate>2025-07-03</signatureDate>
    </ownerSignature>
</ownershipDocument>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
